Pulmatrix (NASDAQ:PULM) and UCB (OTCMKTS:UCBJF) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Institutional & Insider Ownership

3.8% of Pulmatrix shares are held by institutional investors. 26.0% of Pulmatrix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations for Pulmatrix and UCB, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pulmatrix 0 0 1 0 3.00
UCB 0 1 0 0 2.00

Volatility and Risk

Pulmatrix has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, UCB has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.

Earnings and Valuation

This table compares Pulmatrix and UCB’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pulmatrix $150,000.00 109.64 -$20.56 million ($4.98) -0.18
UCB $4.55 billion 3.38 $575.43 million N/A N/A

UCB has higher revenue and earnings than Pulmatrix.

Profitability

This table compares Pulmatrix and UCB’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pulmatrix N/A -151.70% -119.07%
UCB N/A N/A N/A

Summary

Pulmatrix beats UCB on 6 of the 10 factors compared between the two stocks.

About Pulmatrix

Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The company is also involved in developing PUR0200, a reformulation of an existing long-acting antimuscarinic agent that has completed Phase Ib clinical development, which blocks the effects of acetylcholine on muscarinic receptors to reverse airway obstruction in COPD patients. It has a license agreement with RespiVert Ltd. to develop kinase inhibitor for access to a portfolio of novel drug candidates. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

About UCB

UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.